An interventional study of cardiotocograph and Toconaute in Pregnancy Related, sponsored by BioSerenity. Completed at 1 site in France. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-08.
Sponsored by BioSerenity · Not applicable, Interventional, and Other
The purpose of this trial is to create a comparative database, with data obtained with a new monitoring device of pregnant women,Toconaute, and two standard : a clinical cardiotocograph,and an electrophysiological signal medical device. It will allow to optimize the development of this new device.
The use of the Toconaute and/or the electrophysiological medical device will succeed to the usual monitoring of pregnant women with a cardiotocograph. It will not change their medical care.
The trial will include up to 35 pregnant women between 24 and 41 weeks of amenorrhea that requires discontinuous monitoring. It will last about 12 months, with an estimated inclusion period of 11 month.
The main objective is to compare measurements for different gestational age, between: the standard cardiotocograph with those of our device, or between the standard cardiotocograph and the Toconaute and the electrophysiological device, or between the Toconaute and the electrophysiological device.
As a second objective, we want to build a database between the cardiotocograph, the Toconaute and the electrophysiological device, to optimize the development of the Toconaute device.
The trial will include up to 35 healthy adult women pregnant between 24 and 41 weeks of amenorrhea requiring discontinuous monitoring. The trial will not change the usual medical management of women, the Toconaute device will be tested following their usual monitoring. The trial will last approximately 12 months, with an estimated inclusion period of 11 months.
In order to be able to identify possible adverse effects related to the device, women participating simultaneously in another clinical trial can not be included. A delay of 1 month minimum after participation in another clinical trial is requested.
The risks associated with the use of the Toconaute in the trial are considered low and acceptable.
Participating women will receive information from the investigator or the midwife who represents it, and will cover all the points provided for in Article L1122-1. They will be informed of the risks and their right to refuse to participate in a search or to withdraw their consent at any time without incurring any liability or prejudice. Women wishing to participate will receive the newsletter and then sign a consent. A copy of the consent will be issued to them.
As part of the test, the care of the pregnant woman is not changed, the use of the Toconaute will succeed to their usual monitoring with a cardiotocograph. The investigating physician or midwife will therefore follow the recommendations of the usual medical procedure regarding measurements performed by external cardiotocography.
Exclusion Criteria:
monitoring with cardiotocograph and next with the Toconaute of Bioserenity
Device: cardiotocograph · Device: Toconaute
monitoring withardiotocograph and next with Toconaute and next with the electrophysiological device
Device: cardiotocograph · Device: Toconaute · Device: electrophysiological device (Micromed)
monitoring with the cardiotocograph and next with the electrophysiological device (Micromed)
Device: cardiotocograph · Device: electrophysiological device (Micromed)
Monitoring of 20 min with the cardiotocograph
Monitoring of 20 min withToconaute
Monitoring of 20 min with the cardiotocograph
comparison of measures from Toconaute, cardiotocograph and Micromed device
evaluation of the quality of signal (heart rate of mother and foetus, electrocardiogramme mother and foetus, contractions)
Time frame: 1 year
creation of a comparative database between the cardiotocograph and the toconaute and the electrophysiological device (micromed)
databases will be created comparing data from cardiotocograph and data from toconaute and data from the electrophysiological device
Time frame: 1 year
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BioSerenity